卡维地洛与螺内酯联合治疗高龄慢性心力衰竭患者的疗效及安全性分析

目的分析卡维地洛与螺内酯联合治疗高龄慢性心力衰竭（CHF）的临床疗效及安全性。方法将146例高龄慢性心力衰竭患者随机的分为对照组和实验组,对照组患者采取常规强心、利尿剂、扩血管、血管紧张素转换酶抑制剂、抗血小板、调脂等治疗;实验组患者在对照组治疗基础上采取卡维地洛及螺内酯进行治疗,疗程为12周,对两组患者的临床疗效及安全性进行比较。结果实验组总有效率显著高于对照组有效率差异有统计学意义（P〈0.05）,未发现III度AVB,有2例出现II度AVB,停药或减量后消失。结论卡维地洛与螺内酯联合治疗高龄慢性心力衰竭可获得较好疗效,且较安全,值得临床上推广应用。

Efficacy and safety analysis on combined treatment of carredilol and spironolactone to eldly patients with chronic heart failure

Objective Analyzed the clinical efficacy and safety of carvedilol and spironolactone to treat elderly chronic heart failure(CHF).Methods Selected 146 cases of elderly CHF patients,randomly divided into control group and experimental group,control group took conventional cardiac、diuretics、vasodilators、angiotensin converting enzyme inhibitors、antiplatelet and lipid treatment,experimental group taken carvedilol and spironolactone on the basis of control group for treatment,12 weeks,compared two groups’ clinical efficacy and safety.Results Experimental group’s total efficiency rate was significantly higher than control group,there was a statistically significant difference(P<0.05).Conclusion Carvedilol with spironolactone to treat elderly CHF can obtain a good efficacy and relatively safe,is worth for clinical application.